The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

While both the Novavax vaccine and the newest generation of the mRNA Moderna vaccines had been signed off on by about 30 FDA vaccine officials, Prasad ended up writing overrides for each, restricting ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to the Centers for Disease Control and Prevention.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Waning effectiveness and an increased number of infections 6–12 months after the second dose—along with the potential need for booster doses—was expected given that lower neutralising antibody titres ...